Rigel Pharmaceuticals, Inc.
$32.49
▲
0.11%
2026-04-21 09:09:00
www.rigel.com
NMS: RIGL
Explore Rigel Pharmaceuticals, Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$604.16 M
Current Price
$32.49
52W High / Low
$52.24 / $16.11
Stock P/E
1.65
Book Value
$21.38
Dividend Yield
—
ROCE
30.28%
ROE
1.86%
Face Value
—
EPS
$19.48
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
172
Beta
1.27
Debt / Equity
13.62
Current Ratio
2.42
Quick Ratio
2.3
Forward P/E
6.09
Price / Sales
1.83
Enterprise Value
$437.76 M
EV / EBITDA
3.42
EV / Revenue
1.49
Rating
Buy
Target Price
$51.2
EPS Forecast (FY)
—
Pros
- Healthy return on equity.
- Efficient use of capital employed.
- Balance sheet leverage appears manageable.
- Short-term liquidity looks comfortable.
- Strong operating margin profile.
- Net margin remains healthy.
- Valuation is not stretched on P/E basis.
Cons
- Some data points may be missing or delayed because the source is not an official exchange feed.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Spyre Therapeutics, Inc. | $73.39 | — | $5.76 B | — | -30.53% | -25.17% | $75 / $12.25 | $7.16 |
| 2. | Lyell Immunopharma, Inc. | $24.89 | — | $559.6 M | — | -69.37% | -86.98% | $45 / $7.65 | $11.68 |
| 3. | GridAI Technologies Corp. | $2.79 | — | $9.38 M | — | -27% | -58.82% | $5.84 / $0.97 | — |
| 4. | Niagen Bioscience, Inc. | $4.87 | 22.44 | $389.99 M | — | 16.53% | 28.35% | $14.69 / $4.16 | $0.96 |
| 5. | Exicure, Inc. | $3.77 | — | $22.85 M | — | -99.65% | -92.47% | $12.65 / $3.1 | $0.62 |
| 6. | Celcuity Inc. | $120.09 | — | $5.8 B | — | -40.76% | -1.64% | $127.34 / $9.5 | $2.08 |
| 7. | SAB Biotherapeutics, Inc. | $3.86 | 14.78 | $196.16 M | — | -30.19% | 14.96% | $6.6 / $1.3 | $3.18 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 69.8 M | 69.46 M | 101.69 M | 53.33 M | 57.6 M | — |
| Operating Profit | 23.17 M | 28.42 M | 61.1 M | 12.77 M | 16.66 M | — |
| Net Profit | 268.06 M | 27.9 M | 59.61 M | 11.45 M | 14.34 M | — |
| EPS in Rs | 14.51 | 1.51 | 3.23 | 0.62 | 0.78 | 0.7 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 294.28 M | 179.28 M | 116.88 M | 120.24 M |
| Operating Profit | 125.47 M | 24.19 M | -20.49 M | -54.23 M |
| Net Profit | 367.02 M | 17.48 M | -25.09 M | -58.57 M |
| EPS in Rs | 19.86 | 0.95 | -1.36 | -3.17 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 513.59 M | 163.98 M | 117.22 M | 134.28 M |
| Total Liabilities | 122.11 M | 160.69 M | 145.87 M | 147.9 M |
| Equity | 391.48 M | 3.29 M | -28.64 M | -13.62 M |
| Current Assets | 240.17 M | 135.1 M | 99.27 M | 115.9 M |
| Current Liabilities | 99.24 M | 63.3 M | 53.27 M | 65.21 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | 75.66 M | 31.47 M | -5.74 M | -73.76 M |
| Investing CF | -92.36 M | 4.13 M | -4.3 M | 72.78 M |
| Financing CF | 0.6 M | -11.64 M | 18.37 M | 6.55 M |
| Free CF | 75.66 M | 31.07 M | -20.74 M | -74.21 M |
| Capex | — | -0.4 M | -15 M | -0.45 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | 53.38% | -2.79% | — | — |
| Earnings Growth % | 169.69% | 57.16% | — | — |
| Profit Margin % | 9.75% | -21.47% | -48.71% | — |
| Operating Margin % | 13.49% | -17.53% | -45.1% | — |
| Gross Margin % | 89.6% | 93.92% | 98.55% | — |
| EBITDA Margin % | 15.9% | -14.53% | -44.8% | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
| Date | Split |
|---|---|
| 2024-06-27 | 1:0.1 |